Gene Therapy Shows Early Promise for Hydrocephalus Treatment

University of Cincinnati researchers have published a proof-of-concept study on an experimental adeno-associated virus (AAV) gene therapy for hydrocephalus. Tested in animal models, this therapy aims to reduce cerebrospinal fluid overproduction by targeting specific cell types. It offers a less invasive alternative to current surgical treatments, marking a significant step in potential future therapies.